Xenon Pharmaceuticals (XENE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.11
- Estimate
- -$1.16
- Surprise
- +3.9%
- Score today
- 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Xenon Pharmaceuticals (XENE) reported a narrower loss than forecast — adjusted EPS of -$1.11 against the -$1.16 estimate (a 3.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates XENE Sell at 5.0/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +3.9% surprise compares with a -0.2% four-quarter average. Next scheduled report: 2026-11-02.
What argues against it
- Concentration risk — Pipeline: azetukalner
- Quality below floor (1.6 < 4.0)
- Momentum score 1.2/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $36.38
- Price target
- $67.38
- Stop
- $34.99
- Upside to target
- +85.2%
- Reward-to-risk
- 5.7:1
Risk check: RSI 4 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
XENE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.54B
- P/E (fwd)
- -7.8
- 52-week range
- $35.97–$72.66
- Off 52-week high
- 49.9%
- RSI (14)
- 4
- Volume vs avg
- 0.12×
- Score today
- 5.0/10